Drug Profile
Research programme: anti-plasmacytoid dendritic cell antibodies - SBI Biotech
Alternative Names: anti-BST2; SBI-9674Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator SBI Biotech
- Developer Kyowa Kirin; SBI Biotech
- Class Monoclonal antibodies
- Mechanism of Action B cell inhibitors; Dendritic cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Systemic lupus erythematosus
- Discontinued Cancer
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
- 28 Jul 2021 No recent reports of development identified for preclinical development in Systemic-lupus-erythematosus in USA
- 11 Jul 2019 Preclinical development is ongoing in Autoimmune disorders and in systemic lupus erythematosus (SBI Biotech pipeline, July 2019)